Eclutatug

N/A

Report date: 2025/12/25 15:59:56

Base Information

Drug NameEclutatug
Drug Alias NameALE-C04ALE.C04
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionImmunomodulatorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsAnti-Claudin 1
TargetsClaudin 1
Therapy Area/IndicationsHead and Neck NeoplasmsLiver NeoplasmsSquamous Cell Carcinoma of Head and Neck +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSingapore +[8] 
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesInserm
China Registration ClassN/A

Develop Information

Active CompaniesInsermMount Sinai Hospital
Inactive CompaniesAlentis Therapeutics AG
Active IndicationsLiver NeoplasmsCholangiocarcinoma
Inactive IndicationsHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and Neck

Other Information

ATC CodeN/A
Related LinksN/A